title: [Sexual function of men with symptomatic benign prostatic hyperplasia and effect of Tamsulosin].
abstract: OBJECTIVE
  To study the sexual function of men with benign prostatic hyperplasia (BPH) with the lower urinary tract symptoms (LUTS) and the effect of Tamsulosin.
  
  
  METHODS
  One hundred and ninety-two cases of BPH accompanied with typical LUTS were investigated using the International Prostate Symptom Score (IPSS), Quality of Life (QOL), International Index of Erectile Function 5 (IIEF-5) and measuring the flow rate of urine before treatment. The patients were randomly divided into two groups, the treatment group (n = 103) given Tamsulosin 0.2 mg, and the control group (n = 89) taking placebo once a day for 8 weeks. The influence of various factors on sexual function was analyzed before and after treatment.
  
  
  RESULTS
  The mean scores of IPSS, QOL, Qmax and IIEF-5 were (20.20 +/- 6.81), (4.51 +/- 0.76), (9.60 +/- 8.79) ml/s and (9.80 +/- 8.62), respectively. The incidence of erectile dysfunction was 75% (144/192). There was statistically significant correlation between age and IPSS score (r = 0. 203, P < 0. 005) or IIEF-5 score (r = -0.571, P < 0.001) as well as between IPSS and IIEF-5 scores (r = - 0.312, P < 0.001). Various indexes were significantly improved after Tamsulosin treatment as compared with pre-treatment (P < 0.001) and placebo administration (P < 0.001), but no significant difference in various indexes was observed in the control group.
  
  
  CONCLUSIONS
  Age and LUTS are dangerous factors for sexual function, and the severity of LUTS is closely related to the development of sexual dysfunction. Tamsulosin can at once improve the sexual function and the lower urinary tract symptoms of the BPH patients.
authors.affiliation: Department of Urology, First Affiliated Hospital of Henan Science and Technology University, Luoyang, Henan 471003, China. jgzhang@126.com
authors.forename: Jian-Guo
authors.initials: JG
authors.lastname: Zhang
authors.forename: Yan-Li
authors.initials: YL
authors.lastname: Wang
authors.forename: Xiao-Qiang
authors.initials: XQ
authors.lastname: Ren
authors.forename: Zhong-Wei
authors.initials: ZW
authors.lastname: Gao
authors.forename: Yuan-He
authors.initials: YH
authors.lastname: Cheng
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy*; D011788:Quality of Life; D012735:Sexual Dysfunction, Physiological / Q000188:drug therapy / Q000209:etiology; D013449:Sulfonamides / Q000627:therapeutic use*; D011795:Surveys and Questionnaires; D000077409:Tamsulosin; D016896:Treatment Outcome
chemical_list: D000317:Adrenergic alpha-Antagonists; D013449:Sulfonamides; D000077409:Tamsulosin